NSE: WOCKPHARMA · 13 November 2026
- Wockhardt Ltd. shares moved lower in today's trading session, declining by 1.30% to close at ₹2027.20 compared to its previous close of ₹2054.00. The stock opened at ₹2049.60 and traded within a daily range of ₹2012.00 to ₹2075.50.
- Wockhardt reported total revenue of ₹969 crore for the quarter ended September 30, 2026, marking a 24% growth compared to the previous year. The company posted an EBITDA of ₹165 crore and a profit after tax of ₹73 crore, while highlighting robust growth in its biotech operations and progress across international markets.
- Trading volume was 0.63 times the 20-day average daily volume.
Why is Wockhardt share price falling on 13 November 2026?
Wockhardt Ltd. shares moved lower in today's trading session, declining by 1.30% to close at ₹2027.20 compared to its previous close of ₹2054.00. The stock opened at ₹2049.60 and traded within a daily range of ₹2012.00 to ₹2075.50.
The broader market and sectoral benchmarks also experienced downward pressure during the session. The benchmark Nifty index fell by 0.61%, while the sector-specific Nifty Pharma index declined by 0.49%. Wockhardt's 1.30% pullback underperformed both the headline index and its sector peer group, coming on the heels of positive momentum over the prior sessions where the stock posted a return of 0.95% over 1 trading day and 1.11% over 2 trading days, alongside a 5-day return of 1.88% and a 20-day return of 2.07%.
Company disclosures from earlier in the month provide fundamental background without a direct same-day catalyst for today's price action. Wockhardt recently reported its financial performance for the quarter ended September 30, 2026, posting a total revenue of ₹969 crore and a profit after tax of ₹73 crore, alongside updates regarding the expansion of its antibiotic and biosimilar portfolios. Additionally, the company announced the completion of Mr. Vinesh Kumar Jairath's tenure as a Non-Executive Independent Director effective November 9, 2026, and the appointment of Mr. Sumit Garg as Chief Digital & Information Officer as a senior management personnel on November 2, 2026. These recent developments offer context on ongoing corporate governance and business execution but do not represent a direct trigger for today's intraday move.
3.93 lakh shares traded by 13 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 6.26 lakh shares (0.63 times). The five-day average daily volume was 7.97 lakh shares. Separately, the NSE report for 13 November 2026 showed 1.40 lakh shares delivered, representing 35.79% of that day’s traded volume. The same report recorded 23,559 trades.
The stock retreated by 1.30% amid subdued trading volumes following recent positive short-term gains, while broader pharmaceutical stocks and headline indices also traded in negative territory. No specific same-day news or catalyst was reported to directly explain the price movement.
Latest Company Developments
Wockhardt reported total revenue of ₹969 crore for the quarter ended September 30, 2026, marking a 24% growth compared to the previous year. The company posted an EBITDA of ₹165 crore and a profit after tax of ₹73 crore, while highlighting robust growth in its biotech operations and progress across international markets.
Quarterly results and operating performance metrics directly influence investor sentiment and valuation expectations regarding the company's growth trajectory.
The company announced the cessation of Mr. Vinesh Kumar Jairath as a Non-Executive Independent Director following the conclusion of his second consecutive five-year term on November 9, 2026. The required disclosures under SEBI listing regulations were duly submitted to the stock exchanges.
Board and governance updates provide continuity context, though routine director tenure completions do not directly dictate short-term share price movements.
The Board of Directors designated Mr. Sumit Garg as the Chief Digital & Information Officer and Senior Management Personnel of the company effective November 2, 2026. Mr. Garg brings over 30 years of technology and transformation leadership experience across pharmaceutical and global industries.
Leadership additions in digital and technology operations support the company's enterprise transformation and long-term execution capabilities.
30 of the Listing Regulations, please find enclosed Press Release on theUnaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2026.
Wockhardt Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 5.99% on 30 September 2026. This compares with 6.79% on 30 June 2026, a change of -0.80 percentage points.
The filing reported 25 MF/UTI holders.
What to Watch Next
- Execution progress and commercial ramp-up of newly approved novel antibiotics such as Zaynich and Foviscu
- Q3 financial performance and revenue momentum in the international biotech and emerging markets segments
- Cash volume trends and delivery participation relative to the 20-day average volume
- Any further updates regarding the utilization of QIP proceeds as monitored by Crisil Ratings
More Wockhardt news and dated analysis →
Frequently Asked Questions
What is the latest Wockhardt company news?
Wockhardt reported total revenue of ₹969 crore for the quarter ended September 30, 2026, marking a 24% growth compared to the previous year. The company posted an EBITDA of ₹165 crore and a profit after tax of ₹73 crore, while highlighting robust growth in its biotech operations and progress across international markets.
How strong was Wockhardt’s trading volume?
3.93 lakh shares traded, 0.63 times the 20-day average daily volume. The price and volume data are dated 13 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.